Browsing by Author "Kaymak S.U."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Validating the Sexual Adjustment and Body Image Scale (Sabis) with Breast Cancer Patients
    (Springer New York LLC, 2015) Özalp E.; Karslıoğlu E.H.; Aydemir Ö.; Soygür H.; Erkek B.M.; Peker S.E.; Kaymak S.U.
    The purpose of this study was to develop and validate the Sexual Adjustment and Body Image Scale (SABIS), a self-report measure of body image and sexual adjustment for use with Turkish patients with breast cancer. We administered the SABIS to one hundred sixty-nine women who had undergone initial surgical treatment for primary breast cancer. The psychometric properties of the SABIS were examined, and it was found to be a reliable and valid assessment of body image and sexuality in patients with breast cancer following surgery; however, it did not cover all dimensions representing patients’ sexuality and body image. Patients’ sexual problems need to be assessed more comprehensively, using more culturally sensitive items. © 2014, Springer Science+Business Media New York.
  • No Thumbnail Available
    Item
    Reasons for clozapine discontinuation in patients with treatment-resistant schizophrenia
    (Elsevier Ireland Ltd, 2019) Ucok A.; Yağcıoğlu E.A.; Yıldız M.; Kaymak S.U.; Saka M.C.; Taşdelen R.; Danacı A.E.; Şenol Ş.H.
    Although clozapine is more effective than other antipsychotics in the treatment of schizophrenia, the rate of its discontinuation is also high. The aim of this retrospective chart-review study was to investigate the causes of clozapine discontinuation in patients with treatment-resistant schizophrenia. This study included a total of 396 patients with schizophrenia, 240 still on clozapine therapy and 156 who discontinued clozapine, and compared their clinical characteristics. Those who discontinued clozapine had a longer history of illness and more hospitalizations before clozapine and tended to be older. Inadequate response was more common among clozapine discontinuers compared to continuers. The most common reason for discontinuation was the side-effects associated with clozapine (49%). Discontinuation from patient decision or by the psychiatrist due to noncompliance was the second (29.7%) and discontinuation due to lack of efficacy was the third most frequent reason (21.3%). The patients who discontinued clozapine because of cardiac side effects were younger, had shorter duration of clozapine use, and had lower maximum clozapine dose compared to the other discontinuers. Our findings point out the importance of enhancing psychiatrists’ ability to handle manageable side effects to minimize discontinuations and maximize the benefits of clozapine in patients with treatment-resistant schizophrenia. © 2019 Elsevier B.V.